Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03558087
Title Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Matthew Galsky
Indications

invasive bladder transitional cell carcinoma

Therapies

Cisplatin + Gemcitabine + Nivolumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.